Objective: We report the response to pre-operative gemcitabine-based chemoradiotherapy for pancreatic adenocarcinoma. Methods: Thirty-five consecutive patients with borderline resectable pancreatic adenocarcinoma of UICC Stage II or III with portal vein invasion or tumor abutment of artery received radiotherapy (twice daily fractions of 1.5 Gy, 5 days/week, total dose: 36 Gy; 30 Gy for Phase I Level 1) with weekly intravenous infusions of gemcitabine (400, 600 and 800 mg/m 2 ) at Days 1 and 8 for Phase I and 800 mg/m 2 for Phase II. Restaging was repeated after completion of chemoradiotherapy. Results: Twenty-six of the 35 (74.3%) patients underwent resection. The dose-limiting toxicities were Grade 4 neutropenia and thrombocytopenia. The recommended regimen was total radiation dose of 36 Gy with gemcitabine 800 mg/m 2 . Surgical resection was conducted in 11 of the 15 (73.3%) patients in Phase I study and 15 of the 20 (75.0%) in Phase II. After recommended dose chemoradiotherapy and surgical resection, the median disease-free survival was 17.4 months (5-year survival rate ¼ 14.3%). The median overall survival time and 5-year survival rate were 41.2 months and 28.6%, respectively, for the 21 patients who underwent resection and 10.0 months and 0%, respectively, for those 5 who did not (P ¼ 0.004). Conclusion: Our pre-operative gemcitabine-based chemoradiotherapy was well tolerated and safe.
INTRODUCTION
Pancreatic cancer is one of the leading causes of tumor-related mortality. Although long-term survival is only possible with resection, the prognosis of patients after complete resection is often poor since most patients have occult distant metastasis at the time of resection. Consequently, surgical resection alone only provides minimal survival benefits. In this regard, treatment of pancreatic adenocarcinoma Union for International Cancer Control (UICC) Stage II or III is challenging, since resection is often associated with a microscopically positive margin of resection and likely results in local recurrence (1) . Recently, significant improvements in disease-free and overall-survival have been observed in large trials of adjuvant chemotherapy (2, 3) . Especially, pre-operative chemoradiation seems to improve locoregional control. Thus, multimodal approaches using chemoradiation first followed by surgery and adjuvant chemotherapy seem to improve locoregional control, distant metastasis and survival. Pre-operative chemoradiation may also avoid useless surgery in patients with occult distant metastasis or rapidly progressive disease (4) .
Chemoradiation using 5-fluorouracil (5FU) has been the standard therapy for locally advanced pancreatic cancer, with a reported 1-year survival rate ranging from 17 to 28% (5) (6) (7) (8) (9) (10) (11) . Recently, gemcitabine (difluorodeoxycytidine; GEM), a novel nucleoside analog, was reported to have a better effect than 5FU in advanced pancreatic cancer (12) . However randomized controlled trial indicated the addition of GEM to adjuvant 5FU-based chemoradiation was associated with a survival benefit, although this improvement was not statistically significant (13) . Another randomized controlled trial compared adjuvant GEM with 5FU plus folinic acid did not result in improved overall survival in patients with completely resected pancreatic cancer (14) . Twice-a-day continuous radiotherapy with acceleration is a promising modality for irradiation of advanced pancreatic cancer. Accelerated hyperfractionation radiation reduces the total treatment time and repopulation of tumor cells between sessions, resulting in improved local control. In the present study, we applied pre-operative accelerated hyperfractionation radiation with GEM. Specifically, we conducted Phase I and II studies to define the maximum tolerated dose and recommended dose (RD) (Phase I) and assess the efficacy and tolerability of the combination therapy (Phase II).
PATIENTS AND METHODS

ELIGIBILITY AND EVALUATION
A total of 35 patients with not previously treated, borderline resectable pancreatic adenocarcinoma were admitted and treated at Osaka university hospital between January 2002 and December 2006 ( Table 1 ). The institutional review board approved the study and each patient provided a signed informed consent. The eligibility criteria were histopathological or cytologic diagnosis of pancreatic adenocarcinoma, non-metastatic disease of UICC Stage II or III, T3 with 
ENDPOINTS
The primary endpoints were toxicity for Phase I study and efficacy including pathologic response rate of chemoradiation for Phase II. The secondary endpoint were feasibility and tolerability for Phase I study and survival rate, time to treatment failure, response rate, resection rate, recurrence rate and local control rate. The response to treatment was classified into complete response (CR), partial response (PR), stable disease (SD) or progressive disease (PD). CR was defined as disappearance of all target lesions; PR as at least 30% decrease in the sum of diameters of target lesions and no new lesions; PD at least 20% increase in the sum of diameters of target lesions or appearance of new lesions; SD neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. Survival was measured from the date of enrollment to the time of death from any cause. Time to treatment failure was defined as time from enrollment to the first observation of disease progression, death due to any cause or early discontinuation of treatment. Resection rate included the proportion of patients who successfully underwent complete surgical resection with microscopically negative margins.
TREATMENT REGIMEN
CHEMOTHERAPY
Patients were assigned to four sequential dose escalating cohorts of weekly GEM combined with twice-a-day accelerated radiotherapy (Table 2 ). Patients received GEM intravenously over 30 min at Days 1 and 8 with 400 mg/m 2 in Level 1, 2 and 600 mg/m 2 in Level 3 or 800 mg/m 2 in Level 4 and Phase II. Treatment was delayed and/or GEM doses were reduced by 20% for any Grade 3 -4 non-hematological toxicities or Grade 4 hematological toxicities.
RADIOTHERAPY
Radiotherapy was applied 5 days a week for 2 or 3 weeks. Twice-a-day irradiation of the primary pancreatic cancer and regional metastatic lymph nodes with a .1 cm diameter on CT scans was performed (two daily fractions of 1.5 Gy with a minimal 6 h interval between fractions). Four fields were used ( Table 2) .
TOXICITY
Throughout the phases of therapy, patients were evaluated at least weekly by physical examination and laboratory tests to monitor for toxicity. Toxicity was graded by the National Cancer Institute Common Toxicity Criteria (NCI-CTC) Version 2.0 grading system. Treatment toxicity including gastrointestinal symptoms, fever, fatigue, leukopenia, neutropenia, thrombocytopenia, anemia, renal function and high liver function tests was monitored. Dose-limiting toxicity was defined as either the dose inducing Grade 4 neutropenia or Grade 3/4 thrombocytopenia or any Grade 3 -4 nonhematological toxicity.
STATISTICAL CONSIDERATIONS
The sample size was calculated from an expected pathologic response rate (Grade II or more) of 35% and a minimum response rate of 10% with an alpha error of 0.05 and beta error of 0.10. According to Simon's two-stage minimax design, 25 additional patients were required for step two. To minimize the sample size, the step-one patients with the RD were included into the step two. Disease-free survival and overall survival were computed according to the Kaplan -Meier method. The duration of survival was defined as time from enrollment. The endpoint represented any death for overall survival, and local recurrence or metastases for disease-free survival (including deaths observed during treatment). The median follow-up was 20.2 months (4.7 -138.8) for the whole set of patients and 104.5 months (101.0 -138.8) for the four living patients. All analyses were performed with StatView statistical software, version 5.0 (SAS Institute Inc.).
RESULTS
PATIENT CHARACTERISTICS Table 1 (Table 2 ). After completion of the Phase I trial, irradiation with 36 Gy and GEM at 800 mg/m 2 were recommended for Phase II study. In Phase II study, the mean GEM dose was 800 mg/m 2 (100%) at first cycle and 710 mg/m 2 (88.8%) at second cycle. Eight patients interrupted their treatment without a radiation dose reduction. The Grade 3/4 toxicities during chemoradiation included neutropenia 6/0, thrombocytopenia 2/1 and anemia 2/0 in Phase II. No Grade 3 or 4 non-hematological toxicities were observed. Table 3 summarizes the maximum degree of acute toxicity during treatment. No major late toxicities were observed.
SURGICAL PROCEDURE
In Phase I study, eight patients underwent standard pancreaticoduodenectomy (PD) and three underwent distal pancreatectomy with splenectomy (DP). Seven PD with portal vein reconstruction and one DP with en bloc celiac axis resection were performed. In Phase II study, 11 patients underwent PD and 4 underwent DP. Nine PD with portal vein reconstruction and two DP with partial portal vein resection were performed. The mean operative time for PD with the RD (Phase I Level 4 and Phase II) was 626 min (range, 485 -1035 min), and the mean estimated blood loss in those patients was 1845 ml (range, 170 -5500 ml). The mean operative time for DP with the RD was 282 min (range, 230 -335 min), and the mean estimated blood loss in those patients was 548 ml (range, 170 -920 ml). There were only three cases of Grade 1 and two cases of Grade 2 post-operative complications according to Clavien -Dindo's classification (15) . One patient went off study after chemoradiotherapy as a result of superior mesenteric arterial aneurysm. Five patients were operated but not resected due to two cases of small liver metastasis and three cases of peritoneal dissemination. (Fig. 2) . All unresected patients received GEM chemotherapy. No patient who progressed to unresectable responded to be resectable after additional chemotherapy. Eleven (73.3%) patients in Phase I study and 15 (75.0%) patients in Phase II patients underwent tumor resection after chemoradiotherapy with a complete R0 margin-negative resection. Any adjuvant chemotherapy was not performed. Of the 26 who underwent tumor resection, histopathological examination of the effects of chemoradiation was assessed using the grading system for the effect of chemoradiation reported by Evans et al. (16) . None demonstrated a complete pathological response. In Phase I study, treatment effect was judged as Grade I in 1 patient, Grade II in 9 patients (Grade IIa in 3 and IIb in 6) and Grade III in 1 patient. In Phase II study, 10 patients were Grade II (Grade IIa in 6 and IIb in 4) and 5 were Grade III.
OVERALL PATIENT RESPONSE
PATIENT OUTCOME AND SURVIVAL Twenty-six patients received complete R0 margin-negative resection. Four patients of the 15 (26.7%) in Phase I and 5 patients of the 20 (25.0%) in Phase II were considered to have unresectable tumors. Complete resection was performed in 21 patients of the 26 (80.8%) who received the recommended dose. (Fig. 2) . Post-operatively, local recurrences (Table 5 ). Eighteen events were considered for disease-free survival analysis (Fig. 3) . The median disease-free survival rate for patients who underwent resection followed by the RD was 17.4 months. The median survival time was 21.0 months for patients with the RD and 41.2 months for those who underwent tumor resection. Five patients survived .5 years. These long survivors received resection with treatment response of PR or SD. PR and SD were three and two cases, respectively.
DISCUSSION
Previous studies described the benefits of multimodal therapy compared with radiotherapy alone in patients with unresectable disease (17, 18) . For the multimodal therapy, pre-operative chemoradiation provides the following benefits (16): (i) tumors may be downstaged following pre-operative chemoradiation to achieve margin-negative resection.
(ii) Radiation therapy is more effective when applied to well-oxygenated cells with intact vascularization. (iii) Pre-operative chemoradiation may identify those patients with occult distant metastasis or rapidly progressive disease on repeat staging studies after chemoradiation and thus avoid useless surgery (19, 20) . (iv) Pre-operative chemoradiation may also reduce cancer cell seeding during surgery and (v) Full courses of chemoradiation can be delivered preoperatively without potential delays caused by surgical complications and prolonged recovery times, a frequent problem in adjuvant therapy studies. Randomized trials in patients with advanced pancreatic cancer demonstrated the superior survival benefits of GEM compared with 5FU (12, 21, 22) . GEM also improved cancerrelated symptoms and performance status in both treatmentnaive and previously treated patients with metastatic disease. In addition, laboratory studies have demonstrated that GEM also has potent radiosensitizing properties (23 -27) . Therefore, we decided to use a combination of GEM and radiotherapy. Accelerated hyperfractionation radiation shortens the overall treatment duration with same total radiotherapy equivalent dose. It also increases the local control rate without increasing gastrointestinal toxicity (28) . Therefore, we selected accelerated hyperfractionation radiation combined with GEM for pre-operative therapy. The overall toxicity profile of this chemoradiation regimen was excellent, with no Grade 3 or 4 gastrointestinal toxicities.
Wolff et al. (29) One theoretical disadvantage of chemoradiation before surgery is toxicity and radiation-related changes within the tissues in the surgical field that may increase the risk of operation for morbidity and mortality (19) . Project study by the Japanese Society of Hepato-Biliary-Pancreatic Surgery described that operation time was significantly longer in the neoadjuvant group (567 min, range 190 -1160) than in the surgery-first group (496 min, range 161 -1221) (P ¼ 0.0005), but there were no between group differences in blood loss (1400 ml range 60 -8422 vs. 1137 ml range 20 -16201) (P ¼ 0.16), respectively (31). Our mean operative time and blood loss for PD and DP with the RD was 626 min (range, 485 -1035 min) and 282 min (range, 230 -335 min), 1845 ml (range, 170 -5500 ml) and 548 ml (range, 170 -920 ml), respectively. There were no surgery-related complications that could be attributed to the pre-operative therapy.
A pathological CR in the resected pancreas after preoperative chemoradiation is rare in patients with adenocarcinoma of the pancreas (19). Evans et al. (16) reported that Grade IIb or more extensive destruction of tumor (.50%) was seen in 7 of the 17 (41%) patients. Our data on histopathological assessment of the effect of treatment indicated that 13 of the 21 (61.9%) patients who received the RD followed by resection had Grade IIb or more chemoradiation treatment effect (.50% of tumor cells were destroyed) according to the grading system of Evans et al. (15) . The reported rate of Grade II or more chemoradiation treatment effect for 5FU, (19, 20, 30, 32) . Considered together, we speculate that GEM does not only have a superior systemic therapeutic effect but also has radiosensitizing properties greater than those of 5FU and paclitaxel.
A meta-analysis of pre-operative therapy in pancreatic adenocarcinoma was reported (33 -35) . In patients with initially resectable tumors, resection frequencies and survival after neoadjuvant therapy are similar to those of patients with primarily resected tumors and adjuvant therapy. Neoadjuvant treatment appears to have some activity in patients with borderline or unresectable pancreatic adenocarcinoma. Ten neoadjuvant studies with 182 participants with borderline resectable cancer were analyzed by a meta-analytical approach (36) . The 107 patients were resected and the proportion of R0 resection amounted to 83%. The result of the meta-analysis of pre-operative therapy for patients with localized pancreatic cancer indicates a potential advantage for a minority of those with borderline or unresectable lesions. The meta-analysis of neoadjuvant chemoradiotherapy for patients with borderline resectable pancreatic cancer indicated the weighted mean of median survival amounted to 12.4 months (range, 9 -16 months) for the overall cohort of patients, 22.0 months (range, 12 -32 months) for those who were resected and 9.7 months (range, 8 -41 months) for unresected patients (36) . Our overall median survival of 21.0 months in patients who received the RD and 41.2 months in those who underwent resection indicates the potential of pre-operative therapy to improve the outcome of patients with borderline resectable pancreatic cancer. Three of the 21 (14.3%) patients who underwent surgical resection remain alive without evidence of disease recurrence at a minimum follow-up of 104 months.
In conclusion, the present study demonstrated that preoperative GEM-based chemoradiotherapy is well tolerated and safe. Our protocol allowed a high rate of subsequent resection, with encouraging survival data. Multimodal approaches using pre-operative GEM-based chemoradiotherapy followed by surgery and adjuvant chemotherapy would be a promising protocol for borderline resectable pancreatic cancer.
